Biotechnology researchers from SignaBlok will showcase groundbreaking preclinical data on a novel TREM-1 inhibitor at the upcoming Respiratory Innovation Summit and American Thoracic Society (ATS) Conference in San Francisco. The research reveals promising results in experimental models of sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis.
The company’s macrophage-restricted TREM-1 inhibitor demonstrated significant therapeutic potential across multiple disease models. In septic animal studies, the drug provided protection from mortality, with efficacy maintained even when administered at delayed treatment times. Researchers also observed that the inhibitor significantly reduced neutrophil accumulation in lung tissues when administered after lipopolysaccharide (LPS) challenge.
Most notably, in mice with bleomycin-induced pulmonary fibrosis, the TREM-1 blockade demonstrated an ability to reduce disease progression and reverse fibrotic changes in both prevention and treatment models. These findings suggest a potentially transformative approach to managing inflammatory respiratory conditions.
The research centers on TREM-1 (Triggering Receptor Expressed on Myeloid Cells 1), an inflammation amplifier involved in the pathogenesis of several critical respiratory and systemic inflammatory diseases. Traditionally, clinical targeting of TREM-1 has been challenging due to complex ligand interactions.
SignaBlok’s innovative approach leverages its proprietary SCHOOL (Signaling Chain HOmoOLigomerization) technology platform, which enables a novel, ligand-independent method of receptor inhibition. This approach potentially minimizes the risk of therapeutic failure by introducing a unique mechanism of action.
The research will be presented through two poster sessions: one at the Respiratory Innovation Summit and another at the ATS International Conference. Both presentations will be led by Alexander B. Sigalov, Ph.D., the company’s president and principal investigator.
These preclinical findings represent a significant step forward in developing targeted therapies for complex inflammatory conditions, offering hope for more effective treatments for patients suffering from sepsis, ARDS, and pulmonary fibrosis.
This news story relied on a press release distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SignaBlok Presents Promising Preclinical Data on TREM-1 Inhibitor for Inflammatory Respiratory Diseases.